Pixium Vision: management transactions · France · AMF

About Pixium Vision

Pixium Vision is a French medical bioelectronics company focused on developing bionic vision systems for patients who have lost their sight due to retinal degeneration. The company was founded in 2011 and listed in Paris in 2014. It became known for the Prima platform, a wireless subretinal photovoltaic implant combined with smart glasses and a dedicated surgical approach. Its core ambition was to restore partial visual perception and improve autonomy in patients affected in particular by dry age-related macular degeneration (dry AMD), a large unmet medical need with very limited treatment options. Over time, Pixium Vision built its pipeline through feasibility studies and then a pivotal program, PRIMAvera, which was designed as the key clinical step toward a potential European commercialization pathway.\n\nPixium Vision’s business model was centered on the design, clinical assembly and regulatory development of highly advanced implantable devices, integrating surgery, microelectronics, imaging software and visual rehabilitation. Its lead product, the Prima System, evolved through several generations, including upgrades to the implant and to transparent smart glasses. The company conducted implantations in France, Germany, the United Kingdom and the United States, supported by a network of leading academic and clinical partners such as Stanford University, the Institut de la Vision in Paris, Moorfields Eye Hospital in London, the Institute of Ocular Microsurgery in Barcelona, the University Hospital of Bonn and UPMC in Pittsburgh. This international footprint helped reinforce the scientific credibility of the program and its visibility within the MedTech ecosystem.\n\nFrom a market-positioning perspective, Pixium Vision operated in a highly specialized innovation niche at the intersection of implantable medical devices and neurotechnology. The company targeted a sizeable addressable market, but one characterized by high barriers to entry due to stringent clinical, regulatory, industrial and financing requirements. In December 2023, Pixium Vision stated that judicial liquidation would be sought after the review of a takeover offer, together with a delisting application. In January 2024, the court decision was postponed and the proceeding later moved toward judicial liquidation. As of April 23, 2026, Pixium Vision is best understood as a formerly listed pioneer in bionic vision rather than an operating growth company, given the severe financial stress that ultimately reshaped its trajectory. A notable point is that the company was EN ISO 13485 certified and qualified as an “Entreprise Innovante” by Bpifrance.